Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 50 of 50 matching drugs for CSF1R — including drugs targeting any of its 165 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
sunitinib CSF1R Direct yes 5
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CSF1R Direct 3
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib CSF1R Direct 1
biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging CSF1R Direct 1
biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography CSF1R Direct 1
erdafitinib CSF1R Direct 1
gemcitabine, oxaliplatin, imatinib CSF1R Direct 1
gemcitabine, sunitinib CSF1R Direct 1
imatinib, irinotecan, carboplatin CSF1R Direct 1
pexidartinib, durvalumab CSF1R Direct 1
ryz101, everolimus, sunitinib, octreotide, lanreotide CSF1R Direct 1
sunitinib, placebo CSF1R Direct 1
sunitinib, radiation CSF1R Direct 1
sunitinib, sunitinib CSF1R Direct 1
pazopanib CSF1R Direct yes 0
pazopanib hydrochloride CSF1R Direct yes 0
pexidartinib CSF1R Direct yes 0
pexidartinib hydrochloride CSF1R Direct yes 0
sunitinib malate CSF1R Direct yes 0
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3CD SSL via PIK3CD 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel IGF1R SSL via IGF1R 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study IGF1R SSL via IGF1R 2
cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study IGF1R SSL via IGF1R 2
biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging PIK3CD SSL via PIK3CD 1
biopsy, biospecimen collection, copanlisib, radiologic examination PIK3CD SSL via PIK3CD 1
bosutinib CAMK2G SSL via CAMK2G 1
disulfiram, copper, alkylating agents GAPDH SSL via GAPDH 1
disulfiram, copper, alkylating agents SRSF1 SSL via SRSF1 1
insulin degludec, insulin glargine IGF1R SSL via IGF1R 1
laboratory biomarker analysis, linsitinib, pharmacological study, topotecan hydrochloride IGF1R SSL via IGF1R 1
motixafortide, cemiplimab, gemcitabine, nab paclitaxel CXCR4 SSL via CXCR4 1
pantoprazole, omeprazole DDAH1 SSL via DDAH1 1
plerixafor CXCR4 SSL via CXCR4 yes 1
plerixafor, temozolomide, whole-brain radiotherapy (wbrt), radiation therapy CXCR4 SSL via CXCR4 1
radiation therapy, temozolomide, plerixafor, laboratory biomarker analysis, pharmacological study CXCR4 SSL via CXCR4 1
semaglutide, insulin aspart, insulin glargine u100 IGF1R SSL via IGF1R 1
brigatinib IGF1R SSL via IGF1R yes 0
copanlisib PIK3CD SSL via PIK3CD yes 0
copanlisib hydrochloride PIK3CD SSL via PIK3CD yes 0
duvelisib PIK3CD SSL via PIK3CD yes 0
fingolimod S1PR2 SSL via S1PR2 yes 0
fingolimod hydrochloride S1PR2 SSL via S1PR2 yes 0
idelalisib PIK3CD SSL via PIK3CD yes 0
mecasermin IGF1R SSL via IGF1R yes 0
mecasermin rinfabate IGF1R SSL via IGF1R yes 0
pentoxifylline PDE6H SSL via PDE6H yes 0
phenindione GGCX SSL via GGCX yes 0
somatropin IGF1R SSL via IGF1R yes 0
umbralisib PIK3CD SSL via PIK3CD yes 0
umbralisib tosylate PIK3CD SSL via PIK3CD yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.